Dolca Thomas

Dolca Thomas

Directeur/Bestuurslid bij UCB
56 jaar
Health Technology
Finance
Consumer Services

Profiel

Dolca Thomas is Director at Ventus Therapeutics, Inc. since 2021 and Director at Ventus Therapeutics U.S., Inc. since 2021.
Also holds the position of Independent Director at UCB SA starting in 2024 and Senior Advisor & Venture Partner at Samsara BioCapital LLC since 2023.
Formerly Director-Global Clinical Development at Bristol Myers Squibb Co. from 2008 to 2012, Director at PML Computer Centre Pty Ltd. from 2010 to 2015, Director at Juvenile Diabetes Research Foundation from 2012 to 2015, Independent Director at Allakos, Inc. from 2023 to 2025, Independent Director at Chinook Therapeutics, Inc. from 2020 to 2023, Vice President-Clinical Development at Pfizer Inc. from 2012 to 2016, Chief Medical Officer at Principia Biopharma, Inc. from 2018 to 2020, VP & Global Head-Translational Medicine at Roche Group from 2016 to 2018, and Chief Medical Officer, EVP-Research & Development at Equillium, Inc. from 2021 to 2022.
Education includes an undergraduate degree from Cornell University conferred in 1992 and a doctorate from Weill Cornell Medical College conferred in 1997.

Actieve functies van Dolca Thomas

BedrijvenFunctieBegin
UCB Directeur/Bestuurslid 25-04-2024
Directeur/Bestuurslid 01-09-2021
Directeur/Bestuurslid 07-12-2021
Private Equity Investor 01-03-2023

Eerdere bekende functies van Dolca Thomas

BedrijvenFunctieEinde
ALLAKOS INC. Directeur/Bestuurslid 15-05-2025
CHINOOK THERAPEUTICS, INC. Directeur/Bestuurslid 11-08-2023
EQUILLIUM, INC. Hoofd Techniek/Wetenschap/O&O 01-02-2022
PRINCIPIA BIOPHARMA INC. Hoofd Techniek/Wetenschap/O&O 28-09-2020
Corporate Officer/Principal 01-09-2018
Ervaring van Dolca Thomas in detail bekijken

Opleiding van Dolca Thomas

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

96

Eerstegraads connecties

15

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit15

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Consumer Services

Consumer Services

Health Technology

Retail Trade

Finance

Commercial Services

Health Technology

Health Technology

Distribution Services

Health Technology

  1. Beurs
  2. Insiders
  3. Dolca Thomas
-40 %: de beste tools exclusief voor abonnees om de beste beleggingen van morgen te identificeren!
d
:
:
PROFITEER NU